CN113748119A - 一种用作iap抑制剂的smac模拟物的结晶及其制备方法 - Google Patents

一种用作iap抑制剂的smac模拟物的结晶及其制备方法 Download PDF

Info

Publication number
CN113748119A
CN113748119A CN202080030342.1A CN202080030342A CN113748119A CN 113748119 A CN113748119 A CN 113748119A CN 202080030342 A CN202080030342 A CN 202080030342A CN 113748119 A CN113748119 A CN 113748119A
Authority
CN
China
Prior art keywords
degree
compound
formula
crystalline
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080030342.1A
Other languages
English (en)
Other versions
CN113748119B (zh
Inventor
刘迎春
徐招兵
胡利红
丁照中
朱兴训
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN113748119A publication Critical patent/CN113748119A/zh
Application granted granted Critical
Publication of CN113748119B publication Critical patent/CN113748119B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

一种用作IAP抑制剂的SMAC模拟物的结晶及其制备方法，还包括所述结晶在制备治疗受益于cIAP1抑制的癌症的药物中的用途。本申请所述式(I)化合物的结晶稳定性高、吸湿性小，在物理性质、安全性和代谢稳定性方面具有优势，有较高的成药价值。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN202080030342.1A 2019-05-10 2020-05-09 一种用作iap抑制剂的smac模拟物的结晶及其制备方法 Active CN113748119B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019103899708 2019-05-10
CN201910389970 2019-05-10
PCT/CN2020/089437 WO2020228642A1 (zh) 2019-05-10 2020-05-09 一种用作iap抑制剂的smac模拟物的结晶及其制备方法

Publications (2)

Publication Number Publication Date
CN113748119A true CN113748119A (zh) 2021-12-03
CN113748119B CN113748119B (zh) 2024-04-02

Family

ID=73290153

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080030342.1A Active CN113748119B (zh) 2019-05-10 2020-05-09 一种用作iap抑制剂的smac模拟物的结晶及其制备方法

Country Status (13)

Country Link
US (1) US20220177453A1 (zh)
EP (1) EP3967702B1 (zh)
JP (1) JP2022531794A (zh)
KR (1) KR20220006611A (zh)
CN (1) CN113748119B (zh)
AU (1) AU2020274768A1 (zh)
BR (1) BR112021022509A2 (zh)
CA (1) CA3138411A1 (zh)
DK (1) DK3967702T3 (zh)
FI (1) FI3967702T3 (zh)
MX (1) MX2021013729A (zh)
PT (1) PT3967702T (zh)
WO (1) WO2020228642A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101035802A (zh) * 2004-07-02 2007-09-12 健泰科生物技术公司 Iap抑制剂
WO2008014252A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Iap inhibitors
CN101595121A (zh) * 2006-10-12 2009-12-02 诺瓦提斯公司 作为iap抑制剂的吡咯烷衍生物
CN101605786A (zh) * 2006-12-19 2009-12-16 健泰科生物技术公司 细胞凋亡抑制剂的咪唑并吡啶抑制剂
CN101951766A (zh) * 2008-01-24 2011-01-19 泰特拉洛吉克药业公司 凋亡抑制蛋白抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019420B1 (ru) * 2004-12-20 2014-03-31 Дженентех, Инк. Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
AU2018364218B2 (en) * 2017-11-13 2023-03-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. SMAC mimetics used as IAP inhibitors and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101035802A (zh) * 2004-07-02 2007-09-12 健泰科生物技术公司 Iap抑制剂
WO2008014252A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Iap inhibitors
CN101595121A (zh) * 2006-10-12 2009-12-02 诺瓦提斯公司 作为iap抑制剂的吡咯烷衍生物
CN101605786A (zh) * 2006-12-19 2009-12-16 健泰科生物技术公司 细胞凋亡抑制剂的咪唑并吡啶抑制剂
CN101951766A (zh) * 2008-01-24 2011-01-19 泰特拉洛吉克药业公司 凋亡抑制蛋白抑制剂

Also Published As

Publication number Publication date
MX2021013729A (es) 2021-12-10
FI3967702T3 (fi) 2024-04-16
EP3967702A1 (en) 2022-03-16
JP2022531794A (ja) 2022-07-11
PT3967702T (pt) 2024-04-09
KR20220006611A (ko) 2022-01-17
BR112021022509A2 (pt) 2021-12-28
WO2020228642A9 (zh) 2021-10-21
DK3967702T3 (da) 2024-04-15
CN113748119B (zh) 2024-04-02
WO2020228642A1 (zh) 2020-11-19
EP3967702B1 (en) 2024-03-20
AU2020274768A1 (en) 2022-01-06
CA3138411A1 (en) 2020-11-19
US20220177453A1 (en) 2022-06-09
EP3967702A4 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
EP2332934B1 (en) Processes for the preparation of crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide.
EP3191475B1 (en) Crystalline forms of 6-((6, 7-dimethoxyquinazolin-4-yl)oxy) -n,2-dimethylbenzofuran-3-carboxamide
CN108884080A (zh) 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用
EA023103B1 (ru) Замещенный натрий-1н-пиразол-5-олат
US10053452B2 (en) Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine salts and uses thereof
KR20230069983A (ko) Cdk4 억제제의 고체 형태
CN105829323A (zh) 2-(4-(2-(1-异丙基-3-甲基-1H-1,2,4-三唑-5-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]氧氮杂*-9-基)-1H-吡唑-1-基)-2-甲基丙酰胺的多晶型物、其制备方法和药物用途
US20230151015A1 (en) The crystalline forms of a compound
CN113748119B (zh) 一种用作iap抑制剂的smac模拟物的结晶及其制备方法
WO2022257965A1 (zh) 固体形式的周期蛋白依赖性激酶9抑制剂及其用途
EP4116300A1 (en) Crystal of tricyclic compound acting on crbn protein and preparation method therefor
RU2819398C2 (ru) Кристаллическая форма миметика smac, применяемого в качестве ингибитора iap, и способ ее получения
CN113646312B (zh) 固体形式的brd4抑制剂化合物及其制备方法与应用
CN116171156A (zh) 含嘧啶基团的三并环类化合物的盐型、晶型及其制备方法
CN114929695A (zh) 一种irak4抑制剂的结晶及其制备方法
WO2023093861A1 (zh) Axl激酶抑制剂的单对甲苯磺酸盐及其晶型
US20210395232A1 (en) Co-crystal forms of selinexor
EA044623B1 (ru) Кристаллические формы соединения
CN117247382A (zh) 吡啶并嘧啶酮化合物的晶型
KR20200006078A (ko) 화합물의 염 및 그것의 결정 형태
CN112830930A (zh) Eoc317的晶型及其制备方法与应用
CN112513019A (zh) Hcv抑制剂二钠盐晶型c及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063608

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant